The main reason for running clinical trials is to gain approval to sell a new drug or treatment. But clinical trials also present a chance for researchers to understand who will and who won't benefit from a new drug, and -- maybe more importantly -- the experimental measures they test are a source of hope for patients who aren't getting better on existing drugs. Unfortunately, new research shows, cancer treatment trials likely underrepresent low-income populations, raising concerns about the reliability of the data and the quality of care for an already vulnerable population.
Read Full Article »
